sulfanilamide and Glioblastoma studies

Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.

Research Excerpts

Excerpt	Relevance	Reference
"The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor."	7.91	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019)
"The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor."	3.91	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

sulfanilamide and Glioblastoma

Research Excerpts

Research

Studies (1)

Authors

Other Studies

Authors	Studies
Mujumdar, P	1
Kopecka, J	1
Bua, S	1
Supuran, CT	1
Riganti, C	1
Poulsen, SA	1